Equities Analysts Offer Predictions for Equillium, Inc.’s Q3 2024 Earnings (NASDAQ:EQ)

Equillium, Inc. (NASDAQ:EQ) – Equities researchers at Leerink Partnrs boosted their Q3 2024 earnings per share estimates for Equillium in a research note issued on Monday, March 25th. Leerink Partnrs analyst T. Smith now forecasts that the company will post earnings of $0.58 per share for the quarter, up from their prior forecast of $0.50. The consensus estimate for Equillium’s current full-year earnings is ($0.15) per share. Leerink Partnrs also issued estimates for Equillium’s Q4 2024 earnings at $0.03 EPS and FY2028 earnings at $2.32 EPS.

Separately, HC Wainwright decreased their price target on Equillium from $4.50 to $4.00 and set a “buy” rating for the company in a research note on Tuesday, December 26th.

Equillium Stock Performance

Shares of NASDAQ EQ opened at $2.06 on Thursday. The business’s 50-day moving average price is $1.95 and its two-hundred day moving average price is $1.11. Equillium has a one year low of $0.45 and a one year high of $3.25.

Hedge Funds Weigh In On Equillium

Several large investors have recently made changes to their positions in the business. Decheng Capital LLC acquired a new position in Equillium in the 4th quarter valued at approximately $3,215,000. Renaissance Technologies LLC raised its holdings in shares of Equillium by 913.5% in the 2nd quarter. Renaissance Technologies LLC now owns 392,231 shares of the company’s stock worth $294,000 after buying an additional 353,531 shares in the last quarter. JPMorgan Chase & Co. acquired a new position in shares of Equillium in the 1st quarter worth approximately $1,182,000. Integrated Wealth Concepts LLC raised its holdings in shares of Equillium by 56.7% in the 4th quarter. Integrated Wealth Concepts LLC now owns 31,339 shares of the company’s stock worth $33,000 after buying an additional 11,339 shares in the last quarter. Finally, Dimensional Fund Advisors LP acquired a new position in shares of Equillium in the 3rd quarter worth approximately $43,000. Institutional investors and hedge funds own 27.05% of the company’s stock.

About Equillium

Equillium, Inc, a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase Ib clinical trial for the treatment of asthma disease; and Phase Ib clinical trial for the treatment of and lupus nephritis.